Research Funded by Box Rallies

Featured Research

Dr Joanna Achinger and her team recently discovered a pattern of epigenetic changes to the 3-D structure of the DNA that are fundamental to the development of endocrine resistance.

Explore Research

Improved MRI-guided radiotherapy for pancreatic cancer enabled by robust artificial intelligence

NSW

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

NSW

Improving the health and well-being of women cancer survivors

VIC

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

NSW

Investigating why a new brain cancer drug works in some patients but not others

NSW

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

VIC

Linking gut bacteria to the development of early onset colorectal cancer using multi-omic profiling

VIC

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

VIC

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

NSW

Precision Immune-Targeted Gene Silencing to Combat Neuroblastoma Dependency

NSW

Precision targeting of regulatory T cells for solid cancer immunotherapy

VIC

Research Funded by Box Rallies

Featured Research

Improved MRI-guided radiotherapy for pancreatic cancer enabled by robust artificial intelligence

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

Improving the health and well-being of women cancer survivors

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

Investigating why a new brain cancer drug works in some patients but not others

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

Linking gut bacteria to the development of early onset colorectal cancer using multi-omic profiling

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Melanoma Genome Mapping

Melanoma Margins Trial: A Phase III, Multi-centre Randomised Controlled Trial

Monitoring a patient’s real-time response to a new immunotherapy

Nanobody-mediated modulation of unconventional T cells for cancer immunotherapy

New approach to boosting resistance to fungal infection in cancer patients

Novel Treatment Targets in Low-Grade Serous Ovarian Cancer

Overcoming resistance to treat metastatic ER+ breast cancer

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Precision Immune-Targeted Gene Silencing to Combat Neuroblastoma Dependency

Precision targeting of regulatory T cells for solid cancer immunotherapy